191 related articles for article (PubMed ID: 38142407)
1. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies.
Atiq F; Blok R; van Kwawegen CB; Doherty D; Lavin M; van der Bom JG; O'Connell NM; de Meris J; Ryan K; Schols SEM; Byrne M; Heubel-Moenen FCJI; van Galen KPM; Preston RJS; Cnossen MH; Fijnvandraat K; Baker RI; Meijer K; James P; Di Paola J; Eikenboom J; Leebeek FWG; O'Donnell JS
Blood; 2024 Apr; 143(14):1414-1424. PubMed ID: 38142407
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of slightly reduced von Willebrand factor activity.
Bykowska K; Ceglarek B
Pol Arch Intern Med; 2020 Mar; 130(3):225-231. PubMed ID: 31990275
[TBL] [Abstract][Full Text] [Related]
3. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease.
Sanders YV; Groeneveld D; Meijer K; Fijnvandraat K; Cnossen MH; van der Bom JG; Coppens M; de Meris J; Laros-van Gorkom BA; Mauser-Bunschoten EP; Leebeek FW; Eikenboom J;
Blood; 2015 May; 125(19):3006-13. PubMed ID: 25673639
[TBL] [Abstract][Full Text] [Related]
4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
5. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
Sanders YV; van der Bom JG; Isaacs A; Cnossen MH; de Maat MP; Laros-van Gorkom BA; Fijnvandraat K; Meijer K; van Duijn CM; Mauser-Bunschoten EP; Eikenboom J; Leebeek FW;
J Thromb Haemost; 2015 Jun; 13(6):956-66. PubMed ID: 25832887
[TBL] [Abstract][Full Text] [Related]
6. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis.
Kalot MA; Husainat N; El Alayli A; Abughanimeh O; Diab O; Tayiem S; Madoukh B; Dimassi AB; Qureini A; Ameer B; Eikenboom JCJ; Giraud N; McLintock C; McRae S; Montgomery RR; O'Donnell JS; Scappe N; Sidonio RF; Brignardello-Petersen R; Flood VH; Connell NT; James PD; Mustafa RA
Blood Adv; 2022 Jan; 6(1):62-71. PubMed ID: 34610118
[TBL] [Abstract][Full Text] [Related]
7. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.
Atiq F; Meijer K; Eikenboom J; Fijnvandraat K; Mauser-Bunschoten EP; van Galen KPM; Nijziel MR; Ypma PF; de Meris J; Laros-van Gorkom BAP; van der Bom JG; de Maat MP; Cnossen MH; Leebeek FWG;
Br J Haematol; 2018 Jul; 182(1):93-105. PubMed ID: 29767844
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
Flood VH; Christopherson PA; Gill JC; Friedman KD; Haberichter SL; Bellissimo DB; Udani RA; Dasgupta M; Hoffmann RG; Ragni MV; Shapiro AD; Lusher JM; Lentz SR; Abshire TC; Leissinger C; Hoots WK; Manco-Johnson MJ; Gruppo RA; Boggio LN; Montgomery KT; Goodeve AC; James PD; Lillicrap D; Peake IR; Montgomery RR
Blood; 2016 May; 127(20):2481-8. PubMed ID: 26862110
[TBL] [Abstract][Full Text] [Related]
9. Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease.
Quiroga T; Goycoolea M; Belmont S; Panes O; Aranda E; Zúñiga P; Pereira J; Mezzano D
J Thromb Haemost; 2014 Aug; 12(8):1238-43. PubMed ID: 24796601
[TBL] [Abstract][Full Text] [Related]
10. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease.
Biguzzi E; Siboni SM; le Cessie S; Baronciani L; Rosendaal FR; van Hylckama Vlieg A; Peyvandi F
J Thromb Haemost; 2021 Jan; 19(1):96-106. PubMed ID: 32998182
[TBL] [Abstract][Full Text] [Related]
11. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
12. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
[TBL] [Abstract][Full Text] [Related]
13. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
[TBL] [Abstract][Full Text] [Related]
14. Laboratory characterization of obligate carriers of type 3 von Willebrand disease with a potential role for Platelet Function Analyzer (PFA-200).
Geevar T; Dave RG; Mathews NS; Kumar S; Mammen JJ; Vijayan R; Aboobacker FN; Abraham A; Srivastava A; Nair SC
Int J Lab Hematol; 2022 Jun; 44(3):603-609. PubMed ID: 34986515
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand disease and aging: an evolving phenotype.
Sanders YV; Giezenaar MA; Laros-van Gorkom BA; Meijer K; van der Bom JG; Cnossen MH; Nijziel MR; Ypma PF; Fijnvandraat K; Eikenboom J; Mauser-Bunschoten EP; Leebeek FW;
J Thromb Haemost; 2014 Jul; 12(7):1066-75. PubMed ID: 24750783
[TBL] [Abstract][Full Text] [Related]
16. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
Pagliari MT; Rosendaal FR; Ahmadinejad M; Badiee Z; Baghaipour MR; Baronciani L; Benítez Hidalgo O; Bodó I; Budde U; Castaman G; Eshghi P; Goudemand J; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Marino R; Oldenburg J; Peake I; Santoro C; Schneppenheim R; Tiede A; Toogeh G; Tosetto A; Trossaert M; Yadegari H; Zetterberg EMK; Peyvandi F; Federici AB; Eikenboom J
J Thromb Haemost; 2022 May; 20(5):1106-1114. PubMed ID: 35092343
[TBL] [Abstract][Full Text] [Related]
17. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
18. Von Willebrand disease type 2M: Correlation between genotype and phenotype.
Maas DPMSM; Atiq F; Blijlevens NMA; Brons PPT; Krouwel S; Laros-van Gorkom BAP; Leebeek FWG; Nieuwenhuizen L; Schoormans SCM; Simons A; Meijer D; van Heerde WL; Schols SEM
J Thromb Haemost; 2022 Feb; 20(2):316-327. PubMed ID: 34758185
[TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]